TENAX THERAPEUTICS INC (TENX) competitors & alternatives
Health Care · NASDAQ
TENAX THERAPEUTICS INC (TENX)'s top competitors and alternatives — its most similar public companies — include Gilead Sciences (GILD), United Therapeutics (UTHR), Hemab Therapeutics Holdings, Inc. (COAG), VOR BIOPHARMA INC (VOR), EVOMMUNE INC (EVMN), LINEAGE CELL THERAPEUTICS INC (LCTX), Aardvark Therapeutics, Inc. (AARD), Fractyl Health, Inc. (GUTS), AVALYN PHARMA INC (AVLN), ANAPTYSBIO INC (ANAB), RELAY THERAPEUTICS INC (RLAY) and INHIBIKASE THERAPEUTICS INC (IKT). These are TENAX THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top TENX competitors & alternatives
-
Gilead SciencesGILDHealth Care
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis,…
$130.34 (as of 2026-07-22) · market cap $163.6B
-
United TherapeuticsUTHRHealth Care
United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing…
$527.07 (as of 2026-07-22) · market cap $22.7B
-
Hemab Therapeutics Holdings, Inc.COAGHealth Care
Hemab Therapeutics is a clinical-stage biotechnology company developing innovative bispecific and monovalent antibody therapies for serious, rare blood…
$49.23 (as of 2026-07-22) · market cap $2.3B
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
EVOMMUNE INCEVMNHealth Care
Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates…
$11.40 (as of 2026-07-22) · market cap $439M
-
LINEAGE CELL THERAPEUTICS INCLCTXHealth Care
Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships…
$1.11 (as of 2026-07-22) · market cap $278M
-
Aardvark Therapeutics, Inc.AARDHealth Care
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease…
$6.48 (as of 2026-07-22) · market cap $128M
-
Fractyl Health, Inc.GUTSHealth Care
Fractyl Health is a clinical-stage medical device and gene therapy company developing the Revita mucosa resurfacing procedure and Rejuva gene therapy platform…
$0.76 (as of 2026-07-22) · market cap $123M
-
AVALYN PHARMA INCAVLNHealth Care
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases.
$28.72 (as of 2026-07-22) · market cap $1.3B
-
ANAPTYSBIO INCANABHealth Care
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own…
$52.61 (as of 2026-07-22) · market cap $1.6B
-
RELAY THERAPEUTICS INCRLAYHealth Care
A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics.
$19.27 (as of 2026-07-22) · market cap $4.2B
-
INHIBIKASE THERAPEUTICS INCIKTHealth Care
A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no…
$2.17 (as of 2026-07-22) · market cap $287M
Not quite? Describe exactly what you want →
Peers are TENAX THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: TENAX THERAPEUTICS INC (TENX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.